Drugs that contain Deferiprone
1. Ferriprox patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7049328 | CHIESI | Use for deferiprone |
Jun, 2021
(2 years ago) | |
| US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(5 years from now) | |
| US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US11357731 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US11723874 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-859) | Apr 30, 2024 |
| Orphan Drug Exclusivity(ODE-420) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-417) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-421) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-16) | Oct 14, 2018 |
| New Chemical Entity Exclusivity(NCE) | Oct 14, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 14, 2018 |
NCE-1 date: 15 October, 2015
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating transfusional iron overload
Dosage: TABLET;ORAL; SOLUTION;ORAL
How can I launch a generic of FERRIPROX before it's drug patent expiration?
More Information on Dosage
FERRIPROX family patents
